指南与共识呼吸衰竭与机械通气儿科与产科急症

儿童与新生儿ARDS的表面活性物质治疗:ESPNIC专家共识对未来研究步骤的意见

Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps.
指南 / 共识 · Crit Care · 2021-02-22
一句话结论ESPNIC专家共识就儿童与新生儿ARDS表面活性物质治疗的未来研究提出四项强一致声明,强调应依据现行定义和病理生物学知识开展靶向研究。

该专家共识由ESPNIC制定,基于对儿童与新生儿ARDS表面活性物质治疗临床与临床前数据的回顾,旨在为未来研究提供方向。共回顾了8项儿童试验和10项新生儿试验,结果显示氧合改善(儿童7/8项,新生儿7/10项)和病死率改善(儿童3/8项,新生儿1/10项),但试验在患者特征、表面活性物质类型及给药策略方面存在异质性,且研究设计遗漏了关键病理生物学概念。共识就四项声明达成强一致,倡导遵循这些原则开展进一步设计良好的临床前与临床研究。

要点

  • 共识强一致声明1:已有足够临床前和临床数据支持对儿童与新生儿ARDS表面活性物质治疗开展靶向研究,研究应依据现行定义并考虑近期病理生物学知识。
  • 共识强一致声明2:儿童与新生儿ARDS应被视为综合征,临床前研究应依据直接或间接(原发或继发)性质、临床严重度、感染或非感染起源或患者年龄等关键特征进行。
  • 共识强一致声明3:未来儿童与新生儿ARDS试验应优先选择解释性设计而非实用性设计。
  • 共识强一致声明4:儿童与新生儿ARDS需根据试验阶段和设计、触发类型、严重度分级和/或表面活性物质治疗策略选择不同的临床结局。
  • 已回顾的试验中,氧合改善见于儿童7/8项和新生儿7/10项试验,病死率改善见于儿童3/8项和新生儿1/10项试验。

适用人群与场景

  • 患有儿童急性呼吸窘迫综合征(PARDS)的儿童患者。
  • 患有新生儿急性呼吸窘迫综合征(NARDS)的新生儿患者。

研究设计与关键结果

  • 该共识由ESPNIC制定,基于对现有临床和临床前数据的回顾,旨在为未来研究步骤提供信息并推进该领域知识。
  • 共回顾8项儿童ARDS表面活性物质治疗试验和10项新生儿ARDS试验。
  • 氧合改善见于儿童7/8项试验和新生儿7/10项试验;病死率改善见于儿童3/8项试验和新生儿1/10项试验。
  • 试验在患者特征、表面活性物质类型和给药策略方面存在异质性,研究设计遗漏了关键病理生物学概念。
  • 共识就四项声明达成强一致:1. 有足够临床前和临床数据支持对PARDS和NARDS表面活性物质治疗开展靶向研究,研究应依据现行定义并考虑近期病理生物学知识;2. PARDS和NARDS应被视为综合征,临床前研究应依据直接或间接(原发或继发)性质、临床严重度、感染或非感染起源或患者年龄等关键特征进行;3. 未来PARDS和NARDS试验应优先选择解释性设计而非实用性设计;4. PARDS和NARDS需根据试验阶段和设计、触发类型、严重度分级和/或表面活性物质治疗策略选择不同的临床结局。

证据类型、等级与局限

  • 证据类型:专家共识意见。
  • 共识声明以强一致方式达成。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者倡导遵循上述原则开展进一步设计良好的临床前和临床研究,以探讨表面活性物质在PARDS和NARDS中的应用。

指南或共识出处

  • ESPNIC专家共识意见,发表于Crit Care。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS definitions and yielded conflicting results. This is mainly due to heterogeneity in study design reflecting historic lack of pathobiology knowledge. We reviewed the available clinical and preclinical data to create an expert consensus aiming to inform future research steps and advance the knowledge in this area. Eight trials investigated the use of surfactant for ARDS in children and ten in neonates, respectively. There were improvements in oxygenation (7/8 trials in children, 7/10 in neonates) and mortality (3/8 trials in children, 1/10 in neonates) improved. Trials were heterogeneous for patients' characteristics, surfactant type and administration strategy. Key pathobiological concepts were missed in study design. Consensus with strong agreement was reached on four statements: 1. There are sufficient preclinical and clinical data to support targeted research on surfactant therapies for PARDS and NARDS. Studies should be performed according to the currently available definitions and considering recent pathobiology knowledge. 2. PARDS and NARDS should be considered as syndromes and should be pre-clinically studied according to key characteristics, such as direct or indirect (primary or secondary) nature, clinical severity, infectious or non-infectious origin or patients' age. 3. Explanatory should be preferred over pragmatic design for future trials on PARDS and NARDS. 4. Different clinical outcomes need to be chosen for PARDS and NARDS, according to the trial phase and design, trigger type, severity class and/or surfactant treatment policy. We advocate for further well-designed preclinical and clinical studies to investigate the use of surfactant for PARDS and NARDS following these principles.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. De Luca D, Cogo P, Kneyber MC, et al. Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps. Crit Care. 2021. PMID: 33618742. doi:10.1186/s13054-021-03489-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。